Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

NCT05009992 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT05009992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05009992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Recruiting
Start date
October 20, 2021
Completion date
June 30, 2029
Enrollment
360 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, diffuse midline glioma, h3 k27m-mutant, recurrent diffuse intrinsic pontine glioma, recurrent diffuse midline glioma, h3 k27m-mutant, recurrent who grade iii glioma, who grade iii glioma